Candidiasis, Vulvovaginal
4
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BayerClotrimazole vaginal tablet
Sano ChemicalsOCF001 Intravaginal Gel
Merck & Co.CD101 Vaginal Gel
Clinical Trials (3)
Total enrollment: 402 patients across 3 trials
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
Start: Jul 2014Est. completion: Sep 2015240 patients
Phase 4Completed
Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence
Start: Apr 2026Est. completion: Dec 202636 patients
Phase 2Not Yet Recruiting
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
Start: Jun 2016Est. completion: Dec 2016126 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.